Category: headache
PHILADELPHIA -- November 16, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV? (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology.
PHILADELPHIA -- November 16, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV? (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology.
HONOLULU - October 29, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV? (guanfacine) Extended Release Tablets, a
DEERFIELD, Ill., October 14, 2009 -- A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of ≤7 percent compared to either component alone.
September 18, 2009 -- (BRONX, NY) -- An innovative drug-delivery system -- nanoparticles encapsulating nitric oxide or prescription drugs -- shows promise for topical treatment of erectile dysfunction (ED), according to a new study by scientists at Albert Einstein College of Medicine of Yeshiva University.
KANSAS CITY, MO -- September 1, 2009 -- New research on traumatic brain injury (TBI) is being presented this week at the Military Health Research Forum (MHRF), a scientific meeting hosted by the Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP). Service men and women are particularly susceptible to TBI given the nature of combat.
KANSAS CITY, MO -- September 1, 2009 -- New research on treating Gulf War Illness (GWI) is being presented this week at the Military Health Research Forum (MHRF), a scientific meeting hosted by the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP).
August 24, 2009 - (BRONX, NY) - Concussions, whether from an accident, sporting event, or combat, can lead to permanent loss of higher level mental processes. Scientists have debated for centuries whether concussions involve structural damage to brain tissue or whether physiological changes that merely impair the way brain cells function, explain this loss.
Family quarrels and a lack of free time can promote headaches in children. This is what Jennifer Gassmann and her coauthors concluded in their study on risk factors, which appears in the current issue of the Deutsches Ärzteblatt International (Dtsch Arztebl Int 2009; 106[31-32]: 509-16).
PHILADELPHIA -- A new study conducted at the Jefferson Headache Center at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania shows an investigational, orally-inhaled therapy is effective in treating migraines.
STANFORD, Calif. -- Two common anti-influenza drugs -- Relenza and Tamiflu -- appear equally effective at preventing common flu symptoms when given before infection, say researchers from the Stanford University School of Medicine.
Rosemont, Ill -- A new study published in the August 2009 issue of the Journal of Bone and Joint Surgery (JBJS) finds that two years after anterior cervical neck operations, patients who have arthroplasty (disc replacement) or arthodesis (spine fusion) can be expected to have significant improvement in their headache symptoms.
A member of a new class of antiretroviral drugs is safe and effective for patients beginning treatment against HIV, according to researchers who have completed a two-year multisite phase III clinical trial comparing it with standard antiretroviral drugs.
The results are online and scheduled for publication in an upcoming issue of the Lancet.
ARLINGTON HEIGHTS, Ill. -- Migraine headaches are a drain -- not only on the estimated 30 million Americans who suffer from them, but on the economy, too. Because pain and other symptoms caused by migraine headaches can be quite severe, it is projected that nearly $13 billion is spent every year in headache treatment and loss of time from work, which no one can afford these days.
Results of a long-awaited study of 3,070 American adults at Johns Hopkins and 118 other U.S. medical centers show that treatment with either of the two standard antiviral drug therapies is safe and offers the best way for people infected with hepatitis C to prevent liver scarring, organ failure and death.
